Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Saladax Biomedical has received CE mark for its MyPaclitaxel and MyDocetaxel therapeutic dose management (TDM) MyCare assays, enabling commercialisation in the European Union (EU).
Subscribe to our email newsletter
Both paclitaxel and docetaxel are administered based on a body surface area (BSA) calculation.
Saladax’s MyCare technology platform offers automated and rapid in vitro diagnostic tests for patient-specific chemotherapy dose optimization.
Saladax president and CEO Kevin Harter said the MyCare tests, which measure the concentration of paclitaxel or docetaxel in patients’ blood, give oncologists the objective information they need to adjust their patients’ dose to their individual needs.
”Adding MyPaclitaxel and MyDocetaxel to the already available My5-FU assay will allow us to help an even broader segment of patients," Kevin added.
These new tests will enable the physician to know the optimal treatment effectiveness/toxicity balance for different patients.